2019 ARIA Care pathways for allergen immunotherapy

ARIA Working Group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.

OriginalsprogEngelsk
TidsskriftAllergy
ISSN0105-4538
DOI
StatusE-pub ahead of print - 7. apr. 2019

Fingeraftryk

Allergens
Guidelines
Practice Guidelines
Comorbidity
Delivery of Health Care

Citer dette

@article{db73ec7e0495447996aa30e19b9f4b7e,
title = "2019 ARIA Care pathways for allergen immunotherapy",
abstract = "Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.",
keywords = "allergen immunotherapy, asthma, children, mHealth, rhinitis, stratification",
author = "J Bousquet and O Pfaar and A Togias and Sch{\"u}nemann, {H J} and I Ansotegui and Papadopoulos, {N G} and I Tsiligianni and I Agache and Anto, {J M} and C Bachert and A Bedbrook and Bergmann, {K C} and S Bosnic-Anticevich and I Bosse and J Brozek and M Calderon and Canonica, {G W} and L Caraballo and V Cardona and T Casale and L Cecchi and Chu, {D K} and E Costa and Cruz, {A A} and W Czarlewski and Durham, {S R} and {Du Toit}, G and M Dykewicz and M Ebisawa and Fauquert, {J L} and M Fernandez-Rivas and Fokkens, {W J} and J Fonseca and Fontaine, {J F} and {van Wijk}, {R Gerth} and T Haahtela and S Halken and Hellings, {P W} and D Ierodiakonou and T Iinuma and Ivancevich, {J C} and L Jacobsen and M Jutel and I Kaidashev and M Khaitov and O Kalayci and {Kleine Tebbe}, J and L Klimek and Kowalski, {M L} and Lan Le and {ARIA Working Group}",
note = "This article is protected by copyright. All rights reserved.",
year = "2019",
month = "4",
day = "7",
doi = "10.1111/all.13805",
language = "English",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Online",

}

2019 ARIA Care pathways for allergen immunotherapy. / ARIA Working Group.

I: Allergy, 07.04.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - 2019 ARIA Care pathways for allergen immunotherapy

AU - Bousquet, J

AU - Pfaar, O

AU - Togias, A

AU - Schünemann, H J

AU - Ansotegui, I

AU - Papadopoulos, N G

AU - Tsiligianni, I

AU - Agache, I

AU - Anto, J M

AU - Bachert, C

AU - Bedbrook, A

AU - Bergmann, K C

AU - Bosnic-Anticevich, S

AU - Bosse, I

AU - Brozek, J

AU - Calderon, M

AU - Canonica, G W

AU - Caraballo, L

AU - Cardona, V

AU - Casale, T

AU - Cecchi, L

AU - Chu, D K

AU - Costa, E

AU - Cruz, A A

AU - Czarlewski, W

AU - Durham, S R

AU - Du Toit, G

AU - Dykewicz, M

AU - Ebisawa, M

AU - Fauquert, J L

AU - Fernandez-Rivas, M

AU - Fokkens, W J

AU - Fonseca, J

AU - Fontaine, J F

AU - van Wijk, R Gerth

AU - Haahtela, T

AU - Halken, S

AU - Hellings, P W

AU - Ierodiakonou, D

AU - Iinuma, T

AU - Ivancevich, J C

AU - Jacobsen, L

AU - Jutel, M

AU - Kaidashev, I

AU - Khaitov, M

AU - Kalayci, O

AU - Kleine Tebbe, J

AU - Klimek, L

AU - Kowalski, M L

AU - Le, Lan

AU - ARIA Working Group

N1 - This article is protected by copyright. All rights reserved.

PY - 2019/4/7

Y1 - 2019/4/7

N2 - Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.

AB - Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.

KW - allergen immunotherapy

KW - asthma

KW - children

KW - mHealth

KW - rhinitis

KW - stratification

U2 - 10.1111/all.13805

DO - 10.1111/all.13805

M3 - Journal article

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

ER -